New pill aims to keep leukemia in remission for chinese patients
NCT ID NCT07458542
First seen Mar 10, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This study looks at how well and how safely the drug ONUREG (oral azacitidine) works in Chinese adults with acute myeloid leukemia (AML) who are in remission after initial chemotherapy. The 44 participants take ONUREG as a maintenance therapy to help prevent the cancer from coming back. The study tracks relapse-free survival, overall survival, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Hong Kong
Hong Kong, China
Conditions
Explore the condition pages connected to this study.